Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Department of Medicine, Division of Cardiology, Charleston Area Medical Center Institute (CAMC) for Academic Medicine and CAMC Health, Education and Research Institute, Charleston, WV; Department of Medicine, Division of Cardiology, West Virginia University, Charleston Division, Charleston, WV.
Mayo Clin Proc. 2020 Aug;95(8):1613-1620. doi: 10.1016/j.mayocp.2020.05.014. Epub 2020 May 29.
To confirm whether a relationship exists between male sex and coronavirus disease 2019 (COVID-19) mortality and whether this relationship is age dependent.
We queried the COVID-19 Research Network, a multinational database using the TriNetX network, to identify patients with confirmed COVID-19 infection. The main end point of the study was all-cause mortality.
A total of 14,712 patients were included, of whom 6387 (43%) were men. Men were older (mean age, 55.0±17.7 years vs 51.1±17.9 years; P<.001) and had a higher prevalence of hypertension, diabetes, coronary disease, obstructive pulmonary disease, nicotine dependence, and heart failure but a lower prevalence of obesity. Before propensity score matching (PSM), all-cause mortality rate was 8.8% in men and 4.3% in women (odds ratio, 2.15; 95% CI, 1.87 to 2.46; P<.001) at a median follow-up duration of 34 and 32 days, respectively. In the Kaplan-Meier survival analysis, the cumulative probability of survival was significantly lower in men than in women (73% vs 86%; log-rank, P<.001). After PSM, all-cause mortality remained significantly higher in men than in women (8.13% vs 4.60%; odds ratio, 1.81; 95% CI, 1.55 to 2.11; P<.001). In the Kaplan-Meier survival analysis, the cumulative probability of survival remained significantly lower in men than in women (74% vs 86%; log-rank, P<.001). The cumulative probability of survival remained significantly lower in propensity score-matched men than in women after excluding patients younger than 50 years and those who were taking angiotensin-converting enzyme inhibitor or angiotensin receptor blocker medications on admission.
Among patients with COVID-19 infection, men had a significantly higher mortality than did women, and this difference was not completely explained by the higher prevalence of comorbidities in men.
确认男性性别与 2019 年冠状病毒病(COVID-19)死亡率之间是否存在关系,以及这种关系是否与年龄有关。
我们使用 TriNetX 网络查询了 COVID-19 研究网络这一多国家数据库,以确定确诊 COVID-19 感染的患者。本研究的主要终点是全因死亡率。
共纳入 14712 例患者,其中 6387 例(43%)为男性。男性年龄较大(平均年龄 55.0±17.7 岁比 51.1±17.9 岁;P<.001),高血压、糖尿病、冠心病、阻塞性肺疾病、尼古丁依赖和心力衰竭的患病率较高,而肥胖的患病率较低。在进行倾向评分匹配(PSM)之前,男性的全因死亡率为 8.8%,女性为 4.3%(比值比,2.15;95%置信区间,1.87 至 2.46;P<.001),中位随访时间分别为 34 天和 32 天。在 Kaplan-Meier 生存分析中,男性的累积生存率明显低于女性(73%比 86%;对数秩检验,P<.001)。PSM 后,男性的全因死亡率仍明显高于女性(8.13%比 4.60%;比值比,1.81;95%置信区间,1.55 至 2.11;P<.001)。在 Kaplan-Meier 生存分析中,男性的累积生存率仍明显低于女性(74%比 86%;对数秩检验,P<.001)。排除年龄小于 50 岁的患者和入院时服用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂药物的患者后,在匹配的 PSM 男性患者中,其累积生存率仍明显低于女性。
在 COVID-19 感染患者中,男性的死亡率明显高于女性,而这种差异不能完全用男性合并症的更高患病率来解释。